Incidence of Adverse Events
| Adverse event: system organ class preferred term | No. of patients (%) | Highest common toxicity criteria grade (no. of patients) | Relationship to 223Ra dichloride: term (no. of patients) |
| Any adverse event | 6 (100.0) | — | — |
| Gastrointestinal disorders | 4 (66.7) | — | — |
| Nausea | 2 (33.3) | 1 (2) | Possible (2) |
| Abdominal discomfort | 1 (16.7) | 1 (1) | Possible (1) |
| Constipation | 1 (16.7) | 1 (1) | Unlikely (1) |
| Diarrhea | 1 (16.7) | —* | Probable (1) |
| Musculoskeletal and connective tissue disorders | 3 (50.0) | — | — |
| Bone pain | 2 (33.3) | 1 (2) | Unlikely (1) |
| Probable (1) | |||
| Back pain | 1 (16.7) | 1 (1) | Unlikely (1) |
| Blood and lymphatic system disorders | 1 (16.7) | — | — |
| Anemia | 1 (16.7) | 2 (1) | Possible (1) |
| General disorders and administration site conditions | 3 (50.0) | — | — |
| Chest pain | 1 (16.7) | 3 (1) | Possible (1) |
| Disease progression | 1 (16.7) | 5 (1)* | Unlikely (1) |
| Fatigue | 2 (33.3) | 1 (2) | Unlikely (1) |
| Possible (1) | |||
| Infections and infestations | 1 (16.7) | — | — |
| Urinary tract infection | 1 (16.7) | 2 (1) | Unlikely (1) |
| Metabolism and nutrition disorders | 1 (16.7) | — | — |
| Anorexia | 1 (16.7) | —† | Possible (1) |